| Apr 18 |
Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer
|
| Apr 4 |
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
| Mar 18 |
Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer
|
| Mar 14 |
Recap: Verastem Q4 Earnings
|
| Mar 14 |
Verastem GAAP EPS of -$1.02 misses by $0.21
|
| Mar 14 |
Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
|
| Mar 11 |
Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs
|
| Mar 6 |
Verastem gets FDA orphan drug status for low-grade ovarian cancer therapy
|
| Mar 5 |
Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
|
| Mar 5 |
Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024
|
